This study conducted TF-IDF keyword analysis of changes in Pharmaceutical Rebate Regulation (PRR) policy from the 2000 to 2024. Key changes include the dual punishment system (2010), the two-out rebate system (2014), the economic benefit expenditure ...
This study conducted TF-IDF keyword analysis of changes in Pharmaceutical Rebate Regulation (PRR) policy from the 2000 to 2024. Key changes include the dual punishment system (2010), the two-out rebate system (2014), the economic benefit expenditure report system (2018), and the disclosure of expenditure reports and the Contract Sales Organization (CSO) reporting system (2021-2024). The analysis revealed that PRR has evolved from post-sanctions focused on punishing providers to an expanded framework incorporating pre-management through information transparency and CSO institutionalization. Notably, the structural shift of rebate provision from large firms to small-and-medium enterprises and Contract Sales Organizations (CSOs) was empirically supported by significant increases in the TF-IDF weights of related keywords after 2014. These findings highlight the limitations of sanction-only approaches and suggest the necessity of multi-layered, autonomous regulatory governance. This study contributes to enhancing the predictability of policy risks by providing a data-driven understanding of the long-term "regulation-evasion-re-regulation" cycle.